<SEC-DOCUMENT>0001157523-24-000024.txt : 20240105
<SEC-HEADER>0001157523-24-000024.hdr.sgml : 20240105
<ACCEPTANCE-DATETIME>20240105060911
ACCESSION NUMBER:		0001157523-24-000024
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20240104
FILED AS OF DATE:		20240105
DATE AS OF CHANGE:		20240105

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		24514387

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53877934.htm
<DESCRIPTION>INNATE PHARMA S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.12.1.5186
         Copyright 1995 - 2024 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">UNITED
      STATES</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">SECURITIES
      AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; font-weight: bold;">Washington, D.C. 20549</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">FORM
      6-K</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE</div>
    <div style="text-align: center; font-weight: bold;">SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div style="text-align: center; font-weight: bold;">January 4, 2024</div>
    <div style="text-align: center; font-weight: bold;">Commission File Number: 001-39084</div>
    <div>&#160;</div>
    <div style="text-align: center; font-family: 'Times New Roman',Times,serif; font-size: 16pt; font-weight: bold; background-color: rgb(255, 255, 255); color: rgb(0, 0, 0); font-style: normal; font-variant: normal; text-transform: none;">Innate
      Pharma S.A.</div>
    <div style="text-align: center;">(Translation of registrant's name into English)</div>
    <div>&#160;</div>
    <div style="text-align: center;">Innate Pharma S.A.</div>
    <div style="text-align: center;">117 Avenue de Luminy&#8212;BP 30191</div>
    <div style="text-align: center;">13009 Marseille, France</div>
    <div style="text-align: center;">+ 33 (0) 4 30 30 30</div>
    <div style="text-align: center;">(Address of principal executive office)</div>
    <div>&#160;</div>
    <div style="text-align: center;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.</div>
    <div>&#160;</div>
    <div style="text-align: center;">Form 20-F [ X ]&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form 40-F [ ]</div>
    <div>&#160;</div>
    <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
      <div style="page-break-after: always;" class="BRPFPageBreak">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">Innate Pharma S.A.</div>
      <div>&#160;</div>
      <div style="color: #000000;">This Report on Form 6-K shall be deemed to be incorporated by reference in the registration statements on Form F-3 (Nos. 333- 23881 and
        333-265826) of Innate Pharma S.A. (the &#8220;Company&#8221; or &#8220;Innate Pharma&#8221;), to the extent not superseded by documents or reports subsequently filed or furnished by the Company.</div>
      <div>&#160;</div>
      <div style="text-align: center; font-weight: bold;">Press Releases and Announcements</div>
      <div>&#160;</div>
      <div style="color: #000000;">On January 4, 2024, Innate Pharma announced that the U.S. Food and Drug Administration (&#8220;FDA&#8221;) lifted the partial clinical hold placed on
        the lacutamab IND.&#160; On October 5, Innate Pharma announced that the lacutamab IND has been placed on partial clinical hold by the FDA following a recent patient death in the Company&#8217;s ongoing lacutamab trials IPH4102-201 (Phase 2 TELLOMAK) and 102
        (Phase 1b PTCL). The death of a patient affected by S&#233;zary Syndrome was initially considered due to hemophagocytic lymphohistiocytosis (&#8220;HLH&#8221;), a rare hematologic disorder.&#160; The FDA decision to lift the partial clinical hold is based on the FDA
        review of the fatal case which Innate Pharma, together with a steering committee of independent experts, determined to be related to aggressive disease progression and unrelated to lacutamab.</div>
      <div><br>
      </div>
      <div style="color: #000000;">On January 4, 2024, Innate Pharma also announced that it has sought to strengthen the Company&#8217;s leadership and corporate governance with the
        appointment of two new members of the Executive Board of the Company (the &#8220;Executive Board&#8221;). Arvind Sood, Executive Vice President (&#8220;EVP&#8221;), President of U.S. operations and Dr Sonia Quaratino, EVP, Chief Medical Officer are thus joining Herv&#233;
        Brailly, interim Chief Executive Officer (&#8220;CEO&#8221;) and Yannis Morel, EVP, Chief Operating Officer.</div>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z74885046cf0b4f6a9b7253eb5bdc6759" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #000000;">Yannis Morel, the current EVP, Business Development and Product Portfolio Strategy and member of the Executive Board, broadens his remit to become
                EVP, Chief Operating Officer, extending his operational responsibility to the management of research and early development, working with Innate Pharma Chief Scientific Officer Prof. Eric Vivier, and Chief Development Officer, Nicola
                Beltraminelli.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z4f3a153dd9e14fbdaf053503b3a717ed" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #000000;">Dr. Sonia Quaratino, current EVP, Chief Medical Officer is appointed to the Executive Board. Dr. Quaratino joined Innate Pharma in October 2023
                bringing over 25 years of experience in basic research, clinical development, and translational medicine, having worked in academia, global large pharmaceuticals, and biotech companies.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="z48ed34cea862434b857b7fc209a15c94" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #000000;">Arvind Sood joins the Company in a newly created position of EVP, Innate Pharma SA and President of U.S. operations. Mr. Sood is also appointed to the
                Executive Board. Based in the United States, Mr. Sood will be responsible for the execution of the Company&#8217;s U.S. strategy, helping expand the Company&#8217;s investor relations efforts in the United States, and sourcing business development and
                corporate development opportunities in the United States, including liaising with academic institutions and clinical key opinion leaders. Mr. Sood joins Innate Pharma most recently from Amgen and has amassed over four decades of experience
                within large biopharma companies in areas including commercial operations, investor relations and financial communications. Arvind joins Innate Pharma from Amgen, where he most recently served as vice president, Investor Relations. Prior to
                his time at Amgen, Arvind served as senior vice president, Investor Relations and Financial Communications at Aventis S.A. (now Sanofi), based in Paris, France. Arvind also worked at the Upjohn Company (now Pfizer) of Kalamazoo, Michigan,
                where he served in several functions including pharmaceutical sales, marketing and investor relations. He obtained his undergraduate degree in Business Administration from Western Michigan University and his master's degree in Business
                Administration from Central Michigan University..</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <table cellspacing="0" cellpadding="0" id="zdc10c22fc3a64eae9fbbbe49476d1261" class="DSPFListTable" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;">

          <tr>
            <td style="width: 18pt;"><br>
            </td>
            <td style="width: 18pt; vertical-align: top; color: #000000;">&#8226;</td>
            <td style="width: auto; vertical-align: top;">
              <div style="color: #000000;">As previously announced, Herv&#233; Brailly is acting as interim CEO and Chairman of the Executive Board since January 1, 2024, while a permanent successor
                is sought. Mr. Brailly was previously Innate Pharma&#8217;s Chairman of the Supervisory Board. He is a co-founder of the Company and was previously CEO until December 2016.</div>
            </td>
          </tr>

      </table>
      <div><br>
      </div>
      <div style="clear: both; margin-top: 10pt; margin-bottom: 10pt;" class="BRPFPageBreakArea">
        <div style="page-break-after: always;" class="BRPFPageBreak">
          <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
      </div>
      <div>
        <div style="text-align: center; font-weight: bold;">SIGNATURES</div>
        <div>&#160;</div>
        <div style="color: #000000;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
          by the undersigned, thereunto duly authorized.</div>
        <div>&#160;</div>
        <table cellspacing="0" cellpadding="0" border="0" id="z4eafc5a1dfd74e7991f3b6deef1443c4" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; border-collapse: collapse; text-align: left; color: #000000;">

            <tr>
              <td style="width: 50%; vertical-align: bottom;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="color: #000000; font-weight: bold;">INNATE PHARMA S.A.</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: bottom;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: bottom;">
                <div>Date: January 4, 2024</div>
              </td>
              <td style="width: 50%; vertical-align: bottom; border-bottom: 2px solid rgb(0, 0, 0);">
                <div>By: /s/ Herv&#233; Brailly</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: bottom;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom; border-top: 2px solid rgb(0, 0, 0);">
                <div>Name: Herv&#233; Brailly</div>
              </td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: bottom;">&#160;</td>
              <td style="width: 50%; vertical-align: bottom;">
                <div style="color: #000000;">Title: Interim Chief Executive Officer and Chairman of the Supervisory Board</div>
              </td>
            </tr>

        </table>
        <div><br>
        </div>
        <div>&#160;</div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
